Breast cancer is the most common cancer in women and constitutes 18% of all female malignancies. In the United States, breast cancer frequency is approximately 30% of all cancers diagnosed. Most patients with breast cancer succumb to death because of metastasis. As a preventive measure to stop metastatic spread, an efficient local delivery system at the tumor site would be more efficient than systemic drug administration. This approach will be more effective for the primary tumor (without lymph node involvement) at the affected breast or against carcinoma of the breast in situ. Since both of these are localized diseases, the proposed novel delivery system will eliminate tumor cells, resulting in long-term disease-free survival in these patients. We hypothesize that a mucoadhesive in situ gel delivery system containing taxol can be targeted to the cancerous cells where MUC1 gene is overexpressed (compared to normal cells), substantially reducing its toxicity to normal cells. The primary objective of this investigation is to develop a novel sustained release in situ gel delivery system for the targeted local delivery of paclitaxel. The delivery system will be designed so that when injected close to the site of tumor, at the biological pH (7.4), the ionic polymer used in the delivery system will be deprotonated, turning into an instant gel at the injection site. This delivery system could be more effective and safe in the treatment of breast cancer than the conventional systemic administration.
|Effective start/end date||1/1/04 → 12/31/04|
- U.S. Department of Defense: $106,481.00